When is genomic tumour profiling recommended for lung cancer?

The laboratory studies tumour tissue for alterations that can help classify the cancer and identify treatment pathways. Some tests also assess markers used alongside other information when considering immunotherapy.

Testing is particularly relevant when the cancer is advanced, has returned, or needs a new treatment plan. Tissue from a bronchoscopy, biopsy, or operation may be used. If there is too little tissue, the team may discuss another sample or a blood-based test.

Ask your oncology team whether profiling should be completed before treatment begins and which markers are included. The decision depends on the cancer’s type, stage, available tissue, symptoms, and your overall health.

A report may identify a treatment-relevant alteration, a finding that needs more interpretation, or no actionable result. The result is considered with scans, pathology, previous treatment, and your preferences rather than used alone.

Seek urgent medical advice for severe breathlessness, chest pain, coughing blood, new confusion, blue lips, or a fever during cancer treatment. Do not wait for profiling results if breathing or infection symptoms are developing.

Will the result change my first treatment choice? Which molecular markers are included? Is my biopsy large enough for testing? Would a blood sample add useful information? How will you explain findings that do not match an available treatment?